--- title: "Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles" type: "News" locale: "en" url: "https://longbridge.com/en/news/289047382.md" description: "Nan Fung Group Holdings sold 163,957 Oculis shares in Q1 2026 for an estimated $4.3 million, reducing its stake to 7.7% of AUM. The sale preceded Oculis's late-May 2026 Phase 3 trial failure, which caused the stock to drop ~43%. Nan Fung retains a $9.3 million position as its fourth-largest holding." datetime: "2026-06-08T11:25:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289047382.md) - [en](https://longbridge.com/en/news/289047382.md) - [zh-HK](https://longbridge.com/zh-HK/news/289047382.md) --- # Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ## Key Points - Nan Fung Group Holdings sold 163,957 Oculis (OCS) shares in Q1 2026, with an estimated transaction value of $4.3 million. - After the sale, Nan Fung's remaining stake of 350,745 shares was valued at approximately $9.3 million -- representing 7.7% of the fund's assets under management (AUM) -- making Oculis the fourth-largest position in the portfolio. - Oculis shares have fallen sharply following the late-May 2026 failure of its lead Phase 3 program, with the stock down roughly 43% over the past year and underperforming the S&P 500 by approximately 67 percentage points. - 10 stocks we like better than Oculis Ag › ## What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in **Oculis** (NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the trade was $4.3 million, based on the quarter’s average closing price. ## What else to know - Nan Fung's remaining Oculis stake of 350,745 shares was valued at $9.3 million at quarter-end, representing 7.7% of the fund's total AUM and ranking as its fourth-largest holding. - Top holdings after the filing: - NYSE: EVMN: $33.1 million (27.3% of AUM) - NASDAQ: MPLT: $19.7 million (16.3% of AUM) - NASDAQ: LBRX: $15.6 million (12.8% of AUM) - NASDAQ: OCS: $9.3 million (7.7% of AUM) - NASDAQ: INCY: $5.1 million (4.2% of AUM) - As of June 5, 2026, Oculis shares were trading at $11.21 -- down about 43% over the past year, and underperforming the S&P 500 by roughly 67 percentage points. ## Company overview Metric Value Market capitalization $677.0 million Revenue (TTM) 0 Net Income (TTM) ($94.6 million) Dividend yield N/A ## Company snapshot Oculis Holding AG is a clinical-stage biopharmaceutical company developing novel topical therapies for ophthalmic and neuro-ophthalmic diseases. - Oculis targets ophthalmologists and healthcare providers treating patients with diabetic eye disease, dry eye, and neuro-ophthalmic disorders in global markets. - Following the late-May 2026 failure of its Phase 3 DIAMOND trials, Oculis is no longer pursuing FDA approval for OCS-01 in diabetic macular edema. The company is now concentrating its pipeline on two remaining registrational programs: Privosegtor (PIONEER-1, Phase 3 for optic neuropathies, which holds FDA Breakthrough Therapy Designation) and Licaminlimab (PREDICT-1, Phase 2b for dry eye disease). - As of March 31, 2026, the company reported $277.6 million in cash, cash equivalents, and short-term investments, providing a funding runway into the second half of 2029. ## What this transaction means for investors Nan Fung's Q1 trim of its Oculis stake looks less like a vote of no confidence and more like routine portfolio rebalancing. But the context around Oculis has grown considerably more complicated since the end of Q1. On May 29, 2026, Oculis announced that its two Phase 3 DIAMOND trials of OCS-01 -- a topical eye drop for diabetic macular edema -- failed to meet their primary vision endpoints. The company will not pursue FDA approval for that indication and has pivoted its resources toward its two remaining programs: Privosegtor, which holds an FDA Breakthrough Therapy Designation for optic neuritis, and Licaminlimab for dry eye disease. That late-May setback explains much of the dramatic stock slide that has pushed OCS down roughly 43% over the past year. From that perspective, Nan Fung's Q1 sale -- near the $26 range based on quarterly average pricing, much higher than today’s share price of $11-and-change -- predated the bad news and looks relatively well timed. For retail investors, the key question now isn't what Nan Fung did -- it's whether the remaining pipeline justifies the current share price. Oculis is essentially a pre-revenue company that’s burning through roughly $30 to $37 million per quarter in operating expenses. On that front, there is _some_ reason for cautious optimism: Oculis exited Q1 2026 with $277.6 million in cash, with management claiming this provides a runway into the second half of 2029 -- though at recent burn rates, that math requires a meaningful reduction in spending going forward. Provided that happens, this balance sheet cushion gives management time to advance Privosegtor through PIONEER-1 without the immediate pressure of a dilutive capital raise. Still, losing a lead late-stage asset is a significant setback for a company of this size, and investors should watch closely for Privosegtor data updates as the primary near-term catalyst. ## Should you buy stock in Oculis Ag right now? Before you buy stock in Oculis Ag, consider this: The _Motley Fool Stock Advisor_ analyst team just identified what they believe are the **10 best stocks** for investors to buy now… and Oculis Ag wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when **Netflix** made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, **you’d have $443,191**!\* Or when **Nvidia** made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, **you’d have $1,258,838**!\* Now, it’s worth noting _Stock Advisor’s_ total average return is 941% — a market-crushing outperformance compared to 206% for the S&P 500. **Don't miss the latest top 10 list, available with _Stock Advisor_, and join an investing community built by individual investors for individual investors.** See the 10 stocks » _\*Stock Advisor returns as of June 8, 2026._ _Andy Gould has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Incyte. The Motley Fool has a disclosure policy._ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [OCS.US](https://longbridge.com/en/quote/OCS.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [EVMN.US](https://longbridge.com/en/quote/EVMN.US.md) - [MPLT.US](https://longbridge.com/en/quote/MPLT.US.md) - [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md) - [INCY.US](https://longbridge.com/en/quote/INCY.US.md) - [NFLX.US](https://longbridge.com/en/quote/NFLX.US.md) - [OCSAW.US](https://longbridge.com/en/quote/OCSAW.US.md) ## Related News & Research - [12:43 ETOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm](https://longbridge.com/en/news/289083566.md) - [OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm](https://longbridge.com/en/news/288771572.md) - [Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference | OCS Stock News](https://longbridge.com/en/news/289092523.md) - [Riad Sherif: «As a Trained Physician, my Greatest Motivation is to Help Patients in a profound Way.»](https://longbridge.com/en/news/288583305.md) - [08:45 ETXtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target](https://longbridge.com/en/news/289329891.md)